Last reviewed 2026-04-23 · How we verify

AAVCAGsCD59

Janssen Research & Development, LLC · Phase 1 active Biologic

At a glance

Generic name	AAVCAGsCD59
Also known as	HMR59
Sponsor	Janssen Research & Development, LLC
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
AAVCAGsCD59 for the Treatment of Wet AMD (PHASE1)
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 (PHASE1)
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results